PRESEPSIN (SCD14-ST) - A NOVEL BIOMARKER OF NEONATAL SEPSIS
Vaishali S. Bhandare*, Dr. P. E. Jagtap, Dr. Sara Dhanawade, Dr. S. P. Dhonde, Dr. G. J.Belwalkar and Dr. N.S. Nagane
ABSTRACT
Introduction-Despite the continuous research and advances in laboratory services diagnosis of neonatal sepsis remains challenging because of non specific clinical signs and symptoms and unavailability of specific accurate biomarker. Aims & objectives-The present study was undertaken to evaluate the usefulness of new biomolecule Presepsin as diagnostic tool. Material and methods -Study comprises with 140 neonates, out of which 70 neonates were with suspected sepsis and 70 served as full term healthy controls. From birth history it was noted that out of 70 patients 42 were delivered as preterm while 28 were as full term babies. Observation & results-Serum Presepsin was measured from all subjects and found that mean concentration of Presepsin in control group was 318 ± 192.92 pg/ml and that of in study group was 909 ± 207.03 pg/ml which was significantly high than control. The meta-analysis showed the Presepsin levels in preterm patients 913± 209.92 pg/ml while in full term sepsis neonates values were 866.75±168.62 pg/ml. Discussion-Statistically high concentration of Presepsin in study group than control can be justified on the basis of release of Presepsin from breakdown of membrane CD14 and lipopolysaccharide binding protein complex enter into phagosomes and involve in destruction of bacteria by phagocytosis. Concentration of Presepsin released in circulation may have close relation with bacterial count. Full term patients showing low concentration of Presepsin may be due to well developed immune system can control bacterial growth. Conclusion-Our findings offer good support to establish Presepsin as a new reliable biomarker for diagnosis of neonatal sepsis and may serve as reliable diagnostic tool to save these budding lives!.
Keywords: Neonatal sepsis, Presepsin, Preterm, Full term.
[Full Text Article]
[Download Certificate]